Stockscreener 앱 받기
0.5595
0.09%
0.0005
전일 마감가:
$0.559
열려 있는:
$0.5615
하루 거래량:
140.75K
Relative Volume:
0.73
시가총액:
$1.79M
수익:
$232.00K
순이익/손실:
$-12.13M
주가수익비율:
-0.0625
EPS:
-8.9454
순현금흐름:
$-10.29M
1주 성능:
-24.38%
1개월 성능:
-36.42%
6개월 성능:
+0.00%
1년 성능:
+0.00%
1일 변동 폭
$0.5109
$0.567
1주일 범위
$0.5109
$0.7999
52주 변동 폭
$0.5109
$1.1996
Valion Bio Inc Stock (VBIO) Company Profile
명칭
Valion Bio Inc
전화
(888)276-6888
주소
1305 E. HOUSTON STREET, SAN ANTONIO
Compare VBIO vs MOBBW, SHMD, GOODO, PSNYW, DWLD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| 0.00 | 0 | 0 | 0 | 0 | 0.00 | |
MOBBW
Mobilicom Limited Warrants
|
2.45 | 3.33B | 0 | 0 | 0 | 0.00 |
SHMD
Schmid Group N V
|
6.19 | 397.06M | 52.15M | -21.46M | 0 | -0.4675 |
GOODO
Gladstone Commercial Corporation
|
20.19 | 372.90M | 0 | 0 | 0 | 0.00 |
PSNYW
Polestar Automotive Holding Uk
|
2.83 | 254.39M | 2.07B | -1.42B | -1.37B | -0.6765 |
DWLD
Davis Select Worldwide ETF
|
47.19 | 0 | 0 | 0 | 0 | 0.00 |
Valion Bio Inc 주식(VBIO)의 최신 뉴스
VBIO Price Today: Valion Bio, Inc. Stock Price, Quote & Chart | MEXC - MEXC
Valion Bio's Initiative for Radiation Protection Solutions - GuruFocus
House committee directs Pentagon plan for radiation drugs By Investing.com - Investing.com Australia
House committee directs Pentagon plan for radiation drugs - Investing.com UK
Congress presses for radiation drugs that work before and after exposure - Stock Titan
Valion Bio (NASDAQ: VBIO) Confirms U.S. House Armed Services Committee Initiative to Address Urgent Need for Radiation /Nuclear Countermeasures - Sahm
Valion Bio (NASDAQ: VBIO) investors approve major equity plan boost and share issuances - Stock Titan
Valion Bio (VBIO) Stock Analysis Report | Financials & Insights - Benzinga
VBIO News | VALION BIO INC (NASDAQ:VBIO) - ChartMill
VBIO Stock Price, Quote & Chart | VALION BIO INC (NASDAQ:VBIO) - ChartMill
VBIO SEC FilingsValion Bio Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Valion Bio (VBIO) CEO converts 2,206 RSUs, now holds 11,030 shares - Stock Titan
Quest Diagnostics Declares Quarterly Cash Dividend - Weekly Voice
Valion radiation drug, oral option in joint US defense, BARDA briefing - Stock Titan
Valion Bio outlines end-2026 Entolimod GMP validation target as NIAID funds GI-ARS BLA-enabling work - MSN
Valion Bio subsidiary secures exclusive NMR platform license By Investing.com - Investing.com Australia
Valion Bio (VBIO) Reports Financial Position and Strategic Focus for 2026 - GuruFocus
Valion Bio's Velocity Bioworks Secures Exclusive Commercial Lice - GuruFocus
VBIO Technical Analysis & Stock Price Forecast - Intellectia AI
VBIO PE Ratio & Valuation, Is VBIO Overvalued - Intellectia AI
VBIO Should I Buy - Intellectia AI
VALION BIO REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS - GuruFocus
Valion Bio Reports Q1 2026 Earnings and Strategic Outlook - Intellectia AI
Valion Bio Reports Q1 Results, Advances Entolimod Platform - TipRanks
Valion Bio, Inc. Common Stock Q1 2026 Earnings Call Transcript - MarketBeat
Valion Bio, Inc. 1Q 2026: Revenue $24K, Net loss $(6.20M), EPS $(2.23) — 10-Q Summary - TradingView
Valion Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
[10-Q] Valion Bio, Inc. Quarterly Earnings Report - Stock Titan
VBIO: Velocity Bioworks launch and federally funded entolimod development drive 2026 growth outlook - TradingView
Valion Bio subsidiary secures exclusive NMR platform license - Investing.com
Transcript : Valion Bio, Inc., Q1 2026 Earnings Call, May 14, 2026 - marketscreener.com
Valion Bio Q1 2026 Earnings Call: Complete Transcript - Benzinga
Valion Bio reports first quarter 2026 financial results - marketscreener.com
Valion Bio Reports First Quarter 2026 Financial Results - TradingView
Valion Bio (VBIO) widens Q1 2026 loss as it builds TLR5 and CDMO platform - Stock Titan
Valion Bio's Velocity Bioworks Secures Exclusive Commercial License to LarmorBio's BioScan-NMR™ Platform - PR Newswire
Valion Bio Inc (VBIO) Earnings Calendar_Earnings Forecast_Financial Report and Earnings Call - Tiger Brokers
Valion Bio (VBIO.US) will release its earnings report after the market closes on May 14. - Moomoo
Valion Bio to Report First Quarter 2026 Financial Results on May 14, 2026 - Morningstar
VBIO Stock Chart | VALION BIO INC (NASDAQ:VBIO) - ChartMill
3i group (TIVC) files amendment showing 9.99% holding and convertible exposure - Stock Titan
Number of shareholders of Valion Bio, Inc. – NASDAQ:VBIO - TradingView
New San Antonio plant brings 45 jobs, backs radiation drug - Stock Titan
Valion Bio Celebrates Grand Opening of Velocity Bioworks Biomanufacturing Facility in San Antonio, Anchoring Domestic Production of Entolimod™ - Barchart
Valion Bio Appoints Melinda Lackey as General Counsel - The Globe and Mail
Valion Bio Inc (VBIO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Valion Bio Inc 주식 (VBIO) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Valauri Christina Rizopoulos | Director |
Apr 01 '26 |
Buy |
0.95 |
19,000 |
18,008 |
19,000 |
1.27%
1.43%
자본화:
|
볼륨(24시간):